netFormulary Leicestershire Health Community NHS
Medicines Formulary  
 Search
 Formulary Chapter 11: Eye - Full Chapter
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Ranibizumab  (Lucentis)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
For use by specialist ophthalmologists in line with NICE TA 155, TA 274, TA 283 or TA 298 - see links below.
High cost drug excluded to tariff.

Date of entry of decision to Formulary:
Pathological myopia - Feb 2014
RVO - August 2013
DMO - May 2013 
Link  NICE TA 155: Ranibizumab and pegaptanib for ARMD
Link  NICE TA 274: Ranibizumab for treating diabetic macular oedema
Link  NICE TA 283: Ranibizumab for macular oedema secondary to retinal vein occlusion
Link  NICE TA 298: Ranibizumab in pathological myopia
   
Aflibercept  (Eylea)
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
For specialist ophthalmology use only in line with NICE TA 294 for wet ARMD / NICE TA 305 for central retinal vein occlusion / NICE TA 409 for branch retinal vein occlusion and NICE TA 346 for Diabetic Macular Oedema / NICE TA 486 for choroidal neovascularisation
High cost drug excluded to tariff. CCG commissioned

Date of entry of decision to Formulary:
Choroidal neovascularisation - February 2018
Branch RVO - December 2016
DMO - October 2015
Central RVO - April 2014
ARMD - February 2014 
Link  NICE TA 294: Aflibercept in ARMD
Link  NICE TA 305: Aflibercept in macular oedema secondary to central RVO
Link  NICE TA 346: Aflibercept in DMO
Link  NICE TA 409: Aflibercept in Branch RVO
Link  NICE TA 486: Aflibercept for treating choroidal neovascularisation
   
Bevacizumab
View adult BNF View SPC online  Track Changes
Restricted Drug Restricted
Red
High Cost Medicine
Supported by TAS December 2011 for retinopathy of prematurity either first line or as a second line rescue treatment.
High cost drug excluded to tariff  
   
11.08.02  Expand sub section  Vitreomacular traction
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Black

Drugs not recommended for use in the Leicestershire Health Community because of lack of evidence of clinical effectiveness, cost prioritization or concerns over safety. All new drugs will be black until they have been through the appropriate approval process - then they will appear as a specific entry   

Red

Drugs which should be prescribed only by hospital specialists (clinical review by specialist as appropriate and annually as a minimum).  

Amber SCA

Drugs which would initially be prescribed by a hospital specialist and then by a GP where full agreement to share the care of each specific patient has been reached under a LMSG Shared Care Agreement (SCA). Specific patient monitoring or intervention required.   

Amber Simple

Drugs suitable to be initiated and prescribed in primary care only after specialist assessment and recommendation. A shared care agreement is not required.  

Green Conditional

Drugs for which GPs are able to take full responsibility for prescribing and monitoring subject to specified conditions e.g. prescribing in line with agreed LMSG guidance or able to demonstrate suitable competence see comments under individual entries.   

Green

Drugs for which GPs would normally take full responsibility for prescribing and monitoring. Drugs included in this list have been specifically considered by LMSG.   

netFormulary